Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD and gene mutations

JAMA

Volumn 292, Issue 8, 2004, Pages 943-951

  Neumann, Hartmut P H ^a,f   Pawlu, Christian ^a   Pȩczkowska, Mariola ^b   Bausch, Birke ^a   McWhinney, Sarah R ^c   Muresan, Mihaela ^d   Buchta, Mary ^a   Franke, Gerlind ^a   Klisch, Joachim ^a   Bley, Thorsten A ^a   Hoegerle, Stefan ^a   Boedeker, Carsten C ^a   Opocher, Giuseppe ^e   Schipper, Jörg ^a   Januszewicz, Andrzej ^b   Eng, Charis ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c OHIO STATE UNIVERSITY   (United States)

^d CHU NANCY BRABOIS   (France)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUCCINATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CLINICAL FEATURE; DEMOGRAPHY; DISEASE CLASSIFICATION; ENZYME SUBUNIT; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEAD AND NECK TUMOR; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RISK FACTOR; SDHB GENE; SDHD GENE; THYROID CANCER;

EID: 4143105824     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.8.943     Document Type: Article

References (33)

1. Heutink P, van der Mey AGL, Sandkuijl LA, et al. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to 11q23-qter. Hum Mol Genet. 1992;1:7-10.
2. Neumann HPH, Berger DP, Siegmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease. N Engl J Med. 1993;329:1531-1538.
3. Gimm O, Armanios M, Dziema H, et al. Somatic and occult germline mutations in SDHD, a mitochondrial complex II gene, in non-familial pheochromocytomas. Cancer Res. 2000;60:6822-6825.
4. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39:617-622.
5. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981;305:1617-1627.
6. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA. 1996;276:1575-1579.
7. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851.
8. Astuti D, Latif F, Dallol A, et al. Mutations in the mitochondrial complex II subunit SDHB cause susceptibility to familial paraganglioma and pheochromocytoma. Am J Hum Genet. 2001;69:49-54.
9. Cascon A, Ruiz-Llorente S, Cebrian A, et al. Identification of novel SDHD mutations in patients with pheochromocytomas and/or paragangliomas. Eur J Hum Genet. 2002;10:457-461.
10. Neumann HPH, Bausch B, McWhinney SR, et al. Germline mutations in non-syndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466.
11. Milunsky JM, Maher TA, Michels VV, Milunsky A. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. Am J Med Genet. 2001;100:311-314.
12. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001; 69:1186-1197.
13. Taschner PE, Jansen JC, Baysal BE, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer. 2001;31:274-281.
14. Badenhop RF, Cherian S, Lord RS, et al. Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer. 2001;31:255-263.
15. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268-270.
16. Niemann S, Müller U, Engelhardt D, Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum Genet. 2003;113:92-94.
17. Bauters C, Vantyghem MC, Leteurtre E, et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes [letter]. J Med Genet. 2003;40:E75.
18. Baysal BE, Willett-Brozick JE, Andrade Filho PA, et al. A large SDHC genomic deletion between Alu elements causes familial and sporadic paraganglioma. J Med Genet. In press.
19. van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, et al. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet. 1989;2:1291-1294.
20. McWhinney SR, Buchta M, Vanharanta S, et al. Early onset renal cell carcinoma as novel extraparaganglial component of SDHB-associated hereditable paraganglioma. Am J Hum Genet. 2004;74: 153-159.
21. Maher ER, Eng C. The pressure rises: update on the genetics of pheochromocytoma. Hum Mol Genet. 2002;11:2347-2354.
22. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178-183.
23. Giminez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621.
24. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer. 2003;3:193-202.
25. Pacak K, Eisenhofer G, Carasquillo JA, et al. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6-8.
26. Hoegerle S, Nitzsche E, Altehöfer C, et al. Pheochromocytomas: detection with 18F DOPA whole-body PET: initial results. Radiology. 2002;222:507-512.
27. Hoegerle S, Ghanem N, Altehoefer C, et al. 18F-DOPA positron emission tomography for detection of glomus tumours: comparison to MRI. Eur J Nucl Med. 2002;30:689-694.
28. Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340:1872-1879.
29. Sawka AM, Jaeschke R, Singh RJ, Young WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma meta-nephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553-558.
30. Janetschek G, Finkenstedt G, Gasser R, et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol. 1998;160:330-334.
31. Neumann HPH, Bender BU, Reincke M, et al. Adrenal sparing surgery for pheochromocytoma. Br J Surg. 1999;84:94-97.
32. Neumann HPH, Reincke M, Bender BU, et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab. 1999;84: 2608-2610.
33. Walz MK, Peitgen K, Neumann HPH, et al. Endoscopic treatment of solitary, bilateral multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg. 2002;26:1005-1012.